Downloading stories - just a sec.... Lymphoma Information Network - Hodgkin's Disease and the Non-Hodgkin's Lymphomas

Site Navigation

Title Page

Your Host

 

Lymphoma in the News

This section highlights recent or coming news events and allow you to search the internet for breaking stories.  Your tips on breaking news stories are welcome. 

Arthritis and Crohn's Drug Remicade linked to 3 to 6 times increase in lymphoma risk

Drugmaker Johnson & Johnson (NYSE: JNJ) has sent out a letter warning physicians that users of Remicade face an increased risk of developing the deadly cancer lymphoma. Johnson & Johnson reportedly sent out the letter after studies showed that users of Remicade were six times more likely to develop the cancer. Remicade, which is manufactured by Johnson & Johnson's biotechnology unit Centocor, already carries a warning that it can cause serious blood and neurological disorders. The drug, which is based on a monoclonal antibody, is used to treat such autoimmune disorders as Crohn's disease and rheumatoid arthritis.


Links found in genes that cause lymphoma

BALTIMORE, May 15 (AScribe Newswire) -- Using genetically engineered mice, researchers at the Johns Hopkins Children's Center have identified a gene that functions as a cancer-causing gene (or oncogene) and may play a key role in the development of aggressive lymphoma and leukemia in children and adults. Their study, published in the May 15 issue of Cancer Research, focused on the HMG-I gene, whose protein product is overexpressed in several human cancers, but whose exact role in the formation and development of these diseases had been unknown.  Using seven genetically engineered, or transgenic, mice designed to overexpress the HMG-I gene in the lymphoid tissues and white blood cells, the Hopkins researchers found that each mouse quickly developed cases of aggressive leukemia and lymphoma similar to these diseases in human

Article    Aggressive Lymphomas

Feb 25, 2004  -- U.S. researchers have found key links between two genes that interact to block the development of cancer of the lymph nodes or lymphoma. Using specially bred laboratory mice, the Mayo Clinic team provided the first evidence the gene CBP is a tumor suppressor -- and its absence contributes to the formation of lymphoma. The absence of CBP  speeds up the development of lymphoma. In addition, they found that two compounds -- Cyclin E and Skp2 -- control the levels of the controlling protein, known as p27Kip1. "Cancer is not the result of a single defect, but is related to a combination of defects and events," said lead author Dr. Jan van Deursen   Article at MedlinePlus


Seen Recent News?

E-mail your stories in - see the
contact page for addresses.
 

Hepatitis C Linked to Lymphoma

NEW YORK, July 19 (Reuters) - Infection with hepatitis C virus (HCV) nearly doubles the risk of developing non-Hodgkin's lymphoma, a cancer involving the lymph nodes, new research suggests.

Dr. Eric A. Engels of the National Cancer Institute, Rockville, Maryland and colleagues note that studies have shown abnormally high rates of hepatitis C among lymphoma patients, suggesting that the infection raises the risk of lymphoma by chronically stimulating the immune system.

The researchers conclude that there is an association between HCV and non-Hodgkin's lymphoma in the US and that "HCV infection may be one cause of NHL."


Schering receives European approval for Radioimmunotherapy Drug  Zevalin®

January 22, 2004 - Schering AG, Germany announced today that the European Commission has granted marketing approval for its radioimmunotherapy product Zevalin® (ibritumomab tiuxetan). Schering AG received the EU approval for Zevalin® for the treatment of adult patients with rituximab relapsed or refractory CD20-positive follicular B-cell non-Hodgkin’s Lymphoma (NHL). NHL is a type of malignant disease that occurs within the lymphatic system and is the fifth most common cancer after breast, prostate, lung, and colon cancer. Schering AG plans to launch the product in Europe within the next few months.


2004 Study - Hair Dye May Raise Non-Hodgkin's Lymphoma Cancer Risk

Jan 28, 2004 - After years of conflicting studies showing risks and no risks from hair dye for Non-Hodgkin's Lymphoma, a study published in the January 15 issue of the American Journal of Epidemiology by researchers at Yale University said women who dyed their hair starting before 1980 were one-third more likely to develop Non-Hodgkin's lymphoma, or NHL, and those who used the darkest dyes for more than 25 years were twice as likely to develop the cancer.

 


Current News Headlines In Health

Other News Sources

Cancer News on the Net provides news to cancer patients and their families.

More Cancer News Sources

NewsRx  (new name)
Oncolink Cancer News (updated URL)
Doctor's Guide (was Medical News)
National Cancer Institute's Late Breaking News (new URL)
Bone Marrow Transplant Newsletter
Reuters Medical News (new URL)
News Page
The New England Journal of Medicine On-Line (new URL)


Compilation Copyright © 1998-2004 Lymphoma Information Network -
All Rights Reserved

http://www.lymphomainfo.net/

Update: November 11, 2004